Last update 01 Nov 2024
ConjuChem LLC

ConjuChem LLC

Subsidiary Company|
1997|
California, United States
|
10-50
|
www.conjuchem.com

Overview

Tags

Immune System Diseases
Endocrinology and Metabolic Disease
Infectious Diseases
Biological products
Hormone

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease1
Infectious Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Hormone1
Biological products1
Top 5 TargetCount
INSR(Insulin receptor)1

Related

7
Drugs associated with ConjuChem LLC
Albenatide
Target
GLP-1R
Mechanism
GLP-1R modulators
Active Org.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Originator Org.-
Active Indication
Diabetes Mellitus, Type 2
Inactive Indication-
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
PC-DAC Insulin(CONJUCHEM, LLC)
Target
INSR
Mechanism
INSR agonists
Active Org.
ConjuChem LLCConjuChem LLC
Originator Org.
ConjuChem LLCConjuChem LLC
Active Indication
Diabetes Mellitus
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
DAC HIV(ConjuChem LLC)
Target-
Mechanism-
Active Org.
ConjuChem LLCConjuChem LLC
Originator Org.
ConjuChem LLCConjuChem LLC
Active Indication
HIV Infections
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
4
Clinical Trials associated with ConjuChem LLC
NCT01514149 / TerminatedPhase 2
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy
NCT00674466 / CompletedPhase 2
A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Twice-a-week Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy
NCT00638716 / CompletedPhase 2
A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy
100 Clinical Results associated with ConjuChem LLC
Login to view more data
0 Patents (Medical) associated with ConjuChem LLC
Login to view more data
100 Deals associated with ConjuChem LLC
Login to view more data
100 Translational Medicine associated with ConjuChem LLC
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
2
5
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
DAC HIV(ConjuChem LLC)
HIV Infections
More
Preclinical
PC-DAC Insulin(CONJUCHEM, LLC)
 ( INSR )		Diabetes Mellitus
More
Preclinical
CCI-1008
 ( Opioid receptors )		Pain, Postoperative
More
Discontinued
CJC-1131
 ( GLP-1R )		Diabetes Mellitus, Type 2
More
Discontinued
CJC-1004
 ( thrombin )		Thrombosis
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free